Company Description
Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia.
It digitizes the interface between the surgeon and the patient to perform performance-guided surgery for surgeons to deliver outcomes to patients.
The company’s products include Senhance System, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures; instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue.
The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021.
Asensus Surgical, Inc. is headquartered in Durham, North Carolina.
| Country | United States |
| Founded | 2006 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 209 |
| CEO | Anthony Fernando |
Contact Details
Address: 1 Tw Alexander Drive, Suite 160 Durham, North Carolina 27703 United States | |
| Phone | 919-765-8400 |
| Website | asensus.com |
Stock Details
| Ticker Symbol | ASXC |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000876378 |
| CUSIP Number | 04367G103 |
| ISIN Number | US04367G1031 |
| Employer ID | 11-2962080 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Anthony Fernando | President, Chief Executive Officer and Director |
| Shameze Rampertab B.Sc. MBA, CA, CPA | Executive Vice President and Chief Financial Officer |
| Joshua B. Weingard | Chief Legal Officer and Secretary |
| Paul Ziegler Jr., J.D. | Vice President of Sales |
| Ethan Loiselle | Vice President of Global Marketing |
| Amanda Owens | Vice President of People |
| Ravi Kommineni | Head of Global Quality and Regulatory |
| Motti Frimer | Vice President of Research & Development, Digital Solutions and MD of Asensus Surgical |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 17, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jul 15, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jul 5, 2024 | DEFM14A | Filing |
| Jun 24, 2024 | PREM14A | Filing |
| Jun 7, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 7, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 7, 2024 | 8-K | Current Report |
| May 15, 2024 | 8-K | Current Report |
| May 15, 2024 | 8-K | Current Report |
| May 14, 2024 | 10-Q | Quarterly Report |